Comprehensive Financial Consultants Institutional, Inc. Aldeyra Therapeutics, Inc. Transaction History

Comprehensive Financial Consultants Institutional, Inc.

$259 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 11, 2022	SELL	$3.25 - $5.17 $2,600 - $4,136	-800 Closed	0 $0
Q4 2021 Mar 10, 2022	BUY	$3.5 - $9.63 $2,800 - $7,704	800 New	800 $3,000

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.4M

Call Options Held

196K

Put Options Held

142K

Perceptive Advisors LLC New York, NY

9.28M
Shares

$43.6 Million
1.31% of portfolio
Knoll Capital Management, LLC Miami, FL

5.48M
Shares

$25.7 Million
14.56% of portfolio
Vanguard Group Inc Valley Forge, PA

3.76M
Shares

$17.7 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.62M
Shares

$17 Million
0.0% of portfolio
Kennedy Capital Management, Inc. St Louis, MO

1.88M
Shares

$8.84 Million
0.24% of portfolio

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $274M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Comprehensive Financial Consultants Institutional, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Comprehensive Financial Consultants Institutional, Inc. with notifications on news.

Account